Viking Therapeutics (VKTX) Current Assets (2014 - 2026)

Viking Therapeutics (VKTX) has 13 years of Current Assets data on file, last reported at $608.2 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets fell 29.77% year-over-year to $608.2 million; the trailing twelve-month figure through Mar 2026 stood at $608.2 million (down 29.77% YoY), and the FY2025 full-year result was $715.6 million, down 21.12% from the prior year.
• Current Assets declined to $608.2 million in Q1 2026, from $715.6 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $966.3 million in Q1 2024 to a low of $149.5 million in Q1 2023.
• A 5-year average of $559.7 million and a median of $608.2 million in 2026 frame the typical range for Current Assets.
• Across the five-year window, Current Assets jumped 546.52% in 2024 and decreased 29.77% in 2026, its largest moves.
• Tracing VKTX's Current Assets over 5 years: stood at $167.0 million in 2022, then soared by 119.84% to $367.2 million in 2023, then jumped by 147.05% to $907.2 million in 2024, then retreated by 21.12% to $715.6 million in 2025, then declined by 15.01% to $608.2 million in 2026.
• Business Quant data shows VKTX's Current Assets at $608.2 million in Q1 2026, $715.6 million in Q4 2025, and $738.7 million in Q3 2025.